Drug intelligence / Profile preview

GSK4527363

Development stage: Phase 1
Lead developer: GSK
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
Administration: Intravenous, Subcutaneous

Overview

GSK4527363 is a monoclonal antibody under development by GSK for the treatment of systemic lupus erythematosus (SLE). It is designed to recognize and attach to a specific target in the body, with the expected effect of reducing the number of B cells in circulation. The drug is currently being evaluated in a first-in-human Phase 1 clinical trial that includes healthy participants and patients with active SLE. The study aims to assess safety, tolerability, pharmacokinetics, pharmacodynamics, and immunogenicity[1][2][3][4]. As of now, its precise molecular target has not been publicly disclosed.

Beyond the preview

Go deeper on GSK4527363.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK4527363.

Explore the full profile